mercredi 24 janvier 2018

Onco Actu du 24 janvier 2018

1. Biologie

NIH to launch genome editing research program [NIH]

Reckoning the potential of CRISPR/Cas9 tech, NIH launches $190M genome editing research initiative [EndPoints]

1.1 Biologie - Gènes

Study Finds Biological Differences in Lung Tumors of African Americans and Whites [NCI]

2. Etiologie

Roswell Park Research Identifies Link between Smoking, Sex Hormones and Lung Cancer [Roswell Park]

2.7 Etiologie - Obésité

How is Obesity Linked to Cancer? [Cancer Research Catalyst]

3.1 Prévention - Tabac

Derek Yach: Building a Foundation to accelerate an end to smoking [BMJ Blogs]

3.1.1 Prévention - Tabac - e-cigs

E-Cigarettes Likely Encourage Kids To Try Tobacco But May Help Adults Quit [NPR]

Science Group Ranks Evidence on E-Cigarette Safety [NY Times]

4 big takeaways from the most comprehensive report on e-cigarettes yet [Vox]

Vaping Can Be Addictive and May Lure Teenagers to Smoking, Science Panel Concludes [NY Times]

Public Health Consequences of E-Cigarettes [Nation Academis Press]

5.12.10 Immunothérapies - Fusions et acquisitions

Two CARTs, Two Charts: Dissecting Returns From T-Cell Therapy M&A [Life Sci VC]

5.12.2 Immunothérapies - CAR-T

Tmunity nabs $100M for next-gen T-cell immunotherapies [FierceBiotech]

Carl June's Cancer Startup Raises $100 Million From Gilead, Sean Parker [Forbes]

Allied with Penn, Tmunity’s cell therapy pioneers bag $100M mega-round to back a breakthrough quest on CAR-T, CRISPR [EndPoints]

5.12.5 Immunothérapies - Pharma

Merck's Keytruda makes liver-cancer headway, putting BMS and Bayer on notice [FiercePharma]

5.12.9 Immunothérapies - SITC

ChemoCentryx Announces Positive Overall Survival Results with CCR2 Inhibitor CCX872 for Locally Advanced/Metastatic Pancreatic Cancer [ChemoCentryx]

Pancreatic cancer combo sees high survival rates in ChemoCentryx PhIb data [EndPoints]

5.2 Pharma

Puma Biotechnology sinks after Europe unlikely to OK breast cancer drug [Reuters]

Puma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer [Puma]

Puma Biotechnology shares tank after CHMP looks ready to hit a red light on neratinib [EndPoints]

5.2.3 Pharma - économie

Genmab Announces 2017 Net Sales Figures for DARZALEX® (Daratumumab) [Genmab]

5.3 Traitements - FDA, EMA, NICE...

Why EMA matters to European citizens [EMA]

EMA Recommends Refusal of the Marketing Authorisation for Plitidepsin [ESMO]

FDA to begin releasing clinical study reports in pilot programme [BMJ]

6.10 Politiques

German scientists hope for windfall from incoming government [Nature]

6.5 Médecines alternatives

Herbal remedies like St John's Wort can create dangerous clashes with cancer drugs and statins, warn experts [The Telegraph]

6.9 Controverses

Court records show how a medical device ‘seeding trial’ disguised marketing as science [HealthNewsReview]